Several clinically successful tumor-targeting mAbs induce NK cell effector functions. Human NK cells exclusively recognize tumor-bound IgG by the FcR CD16A (FcγRIIIA). Unlike other NK cell activating receptors, the cell surface density of CD16A can be rapidly downregulated in a cis manner by the metalloproteinase ADAM17 following NK cell stimulation in various manners. CD16A downregulation takes place in cancer patients and this may affect the efficacy of tumor-targeting mAbs. We examined the effects of MEDI3622, a human mAb and potent ADAM17 inhibitor, on NK cell activation by antibody-bound tumor cells. MEDI3622 effectively blocked ADAM17 function in NK cells and caused a marked increase in their production of IFNγ. This was observed for NK cells exposed to different tumor cell lines and therapeutic antibodies, and over a range of effector/target ratios. The augmented release of IFNγ by NK cells was reversed by a function-blocking CD16A mAb. In addition, NK92 cells, a human NK cell line that lacks endogenous FcγRs, expressing a recombinant non-cleavable version of CD16A released significantly higher levels of IFNγ than NK92 cells expressing equivalent levels of wildtype CD16A. Taken together, our data show that MEDI3622 enhances the release of IFNγ by NK cells engaging antibody-bound tumor cells by blocking the shedding of CD16A. These findings support ADAM17 as a dynamic inhibitory checkpoint of the potent activating receptor CD16A, which can be targeted by MEDI3622 to potentially increase the efficacy of anti-tumor therapeutic antibodies.
Introduction
CD16A (FcγRIIIA) recognizes IgG 1 and IgG 3 antibodies attached to target cells [1] . This FcR associates with Fcγ and/or CD3ζ chains and is one of the NK cell's most potent activating receptors [2] . Unlike other NK cell activating receptors, CD16A's cell surface density is regulated by a proteolytic process that results in its rapid and efficient downregulation in expression upon antibody engagement and by various other stimuli [3] [4] [5] [6] [7] . This process is referred to as ectodomain shedding and is primarily mediated by a disintegrin and metalloproteinase-17 (ADAM17) [4, 5, 7, 8] . ADAM17 is a membrane-associated protease that cleaves CD16A in a cis manner at a specific location proximal to the cell membrane [7, 8] .
Therapeutic antibodies have been generated against a variety of tumor antigens and tested in clinical trials for assorted malignancies [9] . Several clinically successful tumor-targeting antibodies, such as trastuzumab (anti-HER2) and rituximab (anti-CD20), utilize FcR recognition as a mechanism of action [2, 10] . A limitation of therapeutic antibodies is the development of resistance in patients and the non-responsiveness of some malignancies [11, 12] . Modifying the Fc region of these antibodies to improve their therapeutic efficacy has been a major focus [9, 13] ; however, if CD16A is downregulated in expression, this strategy may have limited effectiveness. Indeed, CD16A downregulation has been reported to occur in the tumor environment of patients, in individuals receiving therapeutics antibodies, and during the ex vivo expansion of NK cells for adoptive transfer into cancer patients [14] [15] [16] [17] [18] .
There have been extensive efforts to develop ADAM17 inhibitors [19] . A primary focus has been on targeting its activity in tumor cells where ADAM17 facilitates the release of various growth factors and adhesion molecules [20] [21] [22] [23] . Initial pharmacological inhibitors of ADAM17 were smallmolecule antagonists [19] . However, to overcome issues of specificity and in vivo half-life, recent efforts have focused on function-blocking antibodies of ADAM17 [24] [25] [26] [27] [28] [29] . MEDI3622 is a human mAb generated through screening scFv phage libraries using ADAM17. Its epitope is distinct from other ADAM17 mAbs and has been mapped to a surface loop unique to the metalloprotease catalytic domain of ADAM17, resulting in high specificity and a potent inhibitory activity [30] . MEDI3622 has been reported to directly inhibit the growth of human head and neck as well as colorectal tumor cells in vitro and in a mouse xenograft model [28, 29] .
We investigated for the first time the effects of blocking ADAM17 with MEDI3622 on NK cell activation induced by therapeutic antibody-bound tumor cells. Cytokine production by NK cells is a key effector function and in particular they are major producers of IFNγ, which has broad anti-cancer activity. This includes crosstalk with leukocytes of the innate and adaptive immunity, induction of ICAM-1 and MHC surface expression on tumor cells that promote leukocyte attachment and stimulation, and inhibition of cell proliferation and angiogenesis in developing and established tumors [31] [32] [33] [34] . We show that combining MEDI3622 with a tumor antigen-targeting antibody greatly augments the production of IFNγ by NK cells and that this is due to blocking CD16A shedding.
Materials and methods

Antibodies
The anti-human mAbs PE-conjugated anti-CD107a (LAMP-1), unconjugated and allophycocyanin-(APC) conjugated anti-CD16 (3G8), PE/Cy7-conjugated anti-CD56 (HCD56), PerCP-conjugated anti-CD3 (UCHT1), and isotype-matched negative control mAbs were purchased from BioLegend (San Diego, CA). APC-conjugated anti-CD62L (L-selectin) was purchased from Ancell (Bayport, MN). APC-conjugated F(ab′) 2 donkey anti-human IgG (H + L) was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). The anti-ADAM17 mAb MEDI3622 was generated from a human phage display library displaying scFv and converted into an IgG 1 , as previously described [28] . Trastuzumab and rituximab, human IgG 1 mAbs, were manufactured by Genentech (South San Francisco, CA). An isotype-matched negative control human IgG 1 antibody was obtained from Sigma (Saint Louis, MO).
Cells
Peripheral blood was obtained from mice housed in a specified pathogen free facility. The human NK cell line NK92 was obtained from ATCC (Manassas, VA) and cultured per the company's instructions. NK92 cells lack endogenous FcγRs [37] , and these cells were stably transduced with pBMN-IRES-EGFP with or without recombinant CD16A or non-cleavable CD16A (also referred to as CD16A-S197P) by retrovirus generation and infection procedures described previously [8] . The Burkitt's lymphoma cell line Raji and ovarian cancer cell SKOV-3 were obtained from ATCC and grown per the company's instructions. The ovarian cancer cell line MA-148 (University of Minnesota, USA) was maintained in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% FBS (Gibco), 100 U/ml penicillin, and 100 U/ml streptomycin (Gibco).
Cell stimulation
Enriched human NK cells and NK92 cells were stimulated with antibody-bound tumor cells as described [5, 8] . Briefly, cells were incubated with the CD20 + Burkitt's lymphoma cell line Raji ± anti-CD20 mAb rituximab (1 µg/ml), or the HER2 + ovarian cancer cell lines SKOV-3 or MA-148 ± the anti-HER2 mAb trastuzumab (1 µg/ml) at an effector:target ratio of 10:1 (320,000 cells: 32,000 cells), unless otherwise specified, and for the indicated time points at 37 °C plus 5% CO 2 . In some experiments, MEDI3622 (1 µg/ml), the selective ADAM17 inhibitor BMS566394 (5 µM) [4, 8] , or the function-blocking anti-CD16 mAb 3G8 (1 µg/ml) was added.
Flow cytometry and ELISA
For cell staining, nonspecific antibody binding sites were first blocked and then the cells were stained with the indicated antibodies and examined by flow cytometry, as previously described [5, 8] . For CD107a detection, PE-conjugated anti-CD107a was added prior to NK cell stimulation and brefeldin and monensin (BD Biosciences, San Jose, CA) were added 1 h after NK cell stimulation. The cells were then incubated for an additional 1 h. For controls, fluorescence minus one was used as well as appropriate isotype-matched antibodies since the cells of interest expressed FcRs. A FSC-A/SSC-A plot was used to set an electronic gate on leukocyte populations, and FSC-A/FSC-H and SSC-A/SSC-H plots were used to set an electronic gate on single cells. A Zombie viability kit was used to assess live vs. dead cells, as per the manufacturer's instructions (BioLegend). ELISA was performed by a cytometric bead-based Flex Set assay for human IFNγ (BD Biosciences) and a LEGENDplex assay for granzyme A and granzyme B (BioLegend), as per the manufacturer's instructions. All flow cytometric analyses were performed on FACSCanto and FACSCelesta instruments using FACSDIVA v8.0.1 (BD Biosciences).
Statistical analyses
Statistical analyses were performed by use of GraphPad Prism (GraphPad Software, La Jolla, CA, USA). After assessing for approximate normal distribution, all variables were summarized as mean ± SD. Comparison between two groups was done with Student's t test, with p < 0.05 taken as statistically significant.
Results
MEDI3622 stains NK cells and blocks ADAM17 function
The anti-ADAM17 mAb MEDI3622 has been reported to have both human and mouse reactivity [28] . We investigated its capacity to recognize human and mouse leukocytes. To verify its specificity for ADAM17, we stained mouse peripheral blood leukocytes from control and conditional ADAM17 knockout mice. The latter mice lacked ADAM17 in their leukocytes. In Fig. 1a , we show that the MEDI3622 mAb stained control mouse leukocytes but not ADAM17-null leukocytes above an isotype control antibody. MEDI3622 also stained peripheral blood leukocytes from healthy human donors (Fig. 1b) , and the staining was typically brighter than mouse leukocytes, which is consistent with its higher affinity [38] . We found that MEDI3622 stained both NK cell populations (Fig. 1c) . CD16A in human NK cells undergoes rapid ectodomain shedding by ADAM17 upon their activation with various stimuli [4, 5, 7, 8] . We examined the effects of MEDI3622 on CD16A downregulation by NK cells upon their stimulation with antibody-bound tumor cells. Enriched peripheral blood NK cells from healthy donors when exposed to MEDI3622, control IgG, and/or SKOV-3 cells, an ovarian cancer cell line that expresses HER2, demonstrated little to no upregulation in expression of the activation marker CD107a (Fig. 2a, panels ii-v) . NK cells exposed to SKOV-3 cells and the anti-HER2 therapeutic mAb trastuzumab underwent a distinct upregulation of CD107a, and these activated cells downregulated their CD16A expression (Fig. 2a, panel vi) . MEDI3622-treated NK cells exposed to SKOV-3 cells and trastuzumab also demonstrated a similar upregulation of CD107a, but their downregulation of CD16A was greatly diminished (Fig. 2a , panels viii vs. vi). This occurred as well for NK cells exposed to trastuzumabbound SKOV-3 cells in the presence of the small molecule ADAM17 inhibitor BMS566394 (Fig. 2a, panel vii) . Hence, in the absence of MEDI3622 we observed a significantly greater percentage of CD107a + CD16A low NK cells and conversely in the presence of MEDI3622 there was a significantly greater percentage of CD107a + CD16A high NK cells following their exposure to trastuzumab-bound tumor cells (Fig. 2a, bar graphs) . The higher surface levels of CD16A retained on NK cells activated by trastuzumab-bound tumor cells when blocking ADAM17 activity are also represented as mean fluorescence intensity (MFI) in Fig. 2b . CD62L is another ADAM17 substrate expressed by NK cells [39] , and its downregulation was also blocked when NK cells were exposed to trastuzumab-bound tumor cells in the presence of MEDI3622 (Fig. 2c) . Taken together, these findings demonstrate that MEDI3622 effectively blocked ADAM17 activity in NK cells, but not their activation.
MEDI3622 enhances IFNγ production by NK cells in the presence of antibody-bound tumor cells
NK cells produce high levels of IFNγ when stimulated by antibody-bound tumor cells [40] . For instance, NK cells exposed to SKOV-3 cells and trastuzumab released significantly higher levels of IFNγ than NK cells when exposed to SKOV-3 cells alone (Fig. 3a) . Remarkably, IFNγ release was further enhanced by MEDI3622-treated NK cells exposed to SKOV-3 cells and trastuzumab, whereas this was not observed by MEDI3622-treated NK cells exposed to SKOV-3 cells alone (Fig. 3a) . We also examined the NK cell cytotoxic granule components granzyme A and granzyme B. We found that the levels released by NK cells exposed to SKOV-3 cells and trastuzumab were significantly higher than NK cells exposed to SKOV-3 cells alone (Fig. 3b) ; however, MEDI3622 treatment of the NK cells did not further increase their release (Fig. 3b) , which is consistent with our earlier observation that blocking ADAM17 activity did not significantly increase ADCC by human NK cells [5] .
The experiments above were performed at an NK cell:tumor cell ratio of 10:1. In patients with solid tumors, NK cells are typically outnumbered by tumor cells [41] . Therefore, we examined the effects of MEDI3622 treatment on IFNγ production by NK cells exposed to trastuzumabbound SKOV-3 cells over a range of effector:target ratios down to 1:10. At all ratios examined, IFNγ production was significantly higher by MEDI3622-treated NK cells (Fig. 3c) . We also examined whether MEDI3622 treatment enhanced IFNγ production by NK cells exposed to other tumor cell lines and therapeutic antibodies. The ovarian cancer cell line MA-148 expresses HER2 at considerably lower levels than SKOV-3 cells (Fig. 4a, histogram plot) . Despite these lower levels of HER2 expression, NK cells again secreted significantly higher levels of IFNγ when exposed to trastuzumab-bound MA-148 cells in the presence of MEDI3622 (Fig. 4a) . Raji is a Burkitt's lymphoma cell line that expresses the tumor-associated antigen CD20, recognized by the therapeutic antibody rituximab. Again, NK cells released the highest levels of IFNγ when exposed to rituximab-bound Raji cells and MEDI3622 (Fig. 4b) .
Role of CD16A shedding in the increased production of IFNγ by MEDI3622-treated NK cells
The mAb 3G8 recognizes the second Ig domain of CD16A and prevents its binding to the Fc region of IgG [42] . We show that 3G8 essentially normalized IFNγ production by NK cells stimulated with trastuzumab-bound SKOV-3 cells in the presence or absence of MEDI3622 (Fig. 5) . Next, we sought to directly address the effects of CD16A shedding on NK cell production of IFNγ when stimulated by antibodybound tumor cells. To do this, we used the immortalized human NK cell line NK92. These cells lack expression of endogenous FcγR yet functional recombinant CD16A can be expressed in these cells [8, 37] . We have reported that substituting the serine at position P2′ adjacent to the ADAM17 cleavage site in CD16A with a proline residue completely disrupts the shedding of this receptor in transduced NK92 cells upon their activation in various manners [8] . We show in Fig. 6a that NK92 cells expressing non-cleavable CD16A (ncCD16A) released significantly higher levels of IFNγ when exposed to SKOV-3 cells in the presence of trastuzumab, establishing that the amino acid substitution did not uncouple CD16A from Fcγ and/or CD3ζ-mediated + NK cells in the indicated contour panels is shown. c Enriched NK cells were treated as described above. CD62L staining levels by CD56 + CD3 − cells are shown. b, c The bar graphs show MFI ± SD of three independent experiments using separate donors. Statistical significance is indicated as **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant signaling. We then compared IFNγ release by NK92 cells expressing wildtype CD16A or ncCD16A at equivalent levels (Fig. 6b) . Similar to primary NK cells, NK92 cells expressing wildtype CD16A produced the highest levels of IFNγ when exposed to trastuzumab-bound SKOV-3 cells in the presence of MEDI3622 (Fig. 6c, panel i) , whereas Secreted IFNγ levels were quantified by ELISA. The bar graphs show mean ± SD of at least three independent experiments using separate donors. Statistical significance is indicated as ****p < 0.0001 MEDI3622 treatment had no effect on IFNγ production by NK92-ncCD16A cells when exposed to trastuzumabbound SKOV-3 (Fig. 6c, panel ii) . NK92-ncCD16A cells, however, produced significantly higher levels of IFNγ than NK92-CD16A cells when exposed to trastuzumab-bound SKOV-3 cells (Fig. 6c, panel iii) . Taken together, these findings indicate that MEDI3622 increased IFNγ production by NK cells exposed to antibody-bound tumor cells primarily by blocking the shedding of CD16A and not other ADAM17 substrates.
Discussion
ADAM17 is a membrane-associated metalloprotease that undergoes a rapid increase in its catalytic activity upon leukocyte stimulation and cleaves various cell surface receptors [43] . We report here that the highly specific ADAM17 mAb MEDI3622 binds to human NK cells and blocks the downregulation of ADAM17 substrates upon their activation by antibody-bound tumor cells. These NK cells also demonstrated a marked enhancement in their production of IFNγ. Increased IFNγ release occurred for MEDI3622-treated NK cells exposed to trastuzumab-bound ovarian cancer cell lines, both MA-148 and SKOV-3 expressing low and high levels of HER2, respectively, as well as rituximab-bound Raji cells, a Burkitt's lymphoma cancer cell line. The ratio of NK cells to cancer cells in the tumor environment varies widely due to many circumstances, and in patients with solid tumors, NK cells are typically outnumbered by tumor cells [41] . We found that over a range of effector:target ratios, MEDI3622-treated NK cells consistently produced higher levels of IFNγ in the presence of antibody-bound tumor cells, indicating that blocking ADAM17 activity in NK cells could result in their increased production of IFNγ in the tumor environment at all levels of infiltration. Our data demonstrate that an anti-CD16A function-blocking mAb neutralized this augmented production of IFNγ. In The bar graph shows mean ± SD of at least three independent experiments using separate donors. Statistical significance is indicated as ****p < 0.0001 Representative data from at least three independent experiments are shown. c NK92 cells expressing wildtype CD16A or ncCD16A were incubated with SKOV-3 cells, trastuzumab, and/or MEDI3622, as indicated, for 4 h at 37 °C. Secreted IFNγ levels were quantified by ELISA and shown as fold change normalized to NK cells exposed to SKOV-3 cells alone. a, c The bar graphs show mean ± SD of at least three independent experiments. Statistical significance is indicated as ***p < 0.001;****p < 0.0001; ns not significant addition, NK92 cells expressing a non-cleavable version of CD16A released a significantly higher amount of IFNγ than NK92 cells expressing equivalent levels of wildtype CD16A when exposed to antibody-bound tumors cells. These findings provide the first direct evidence that CD16A shedding modulates IFNγ production by NK cells and underlies the effects of MEDI3622 on NK cells.
CD16A signaling in NK cells also results in their exocytosis of cytotoxic granules [2] . We have reported that ADAM17 inhibition did not significantly enhance tumor cell killing by an ADCC assay [5] . Consistent with this, we also did not see a significant difference in the levels of granzyme A and granzyme B released by NK cells exposed to trastuzumab-bound SKOV-3 cells in the absence or presence of MEDI3622. A limitation of some in vitro ADCC assays, however, is that they assess the cumulative lytic hit by NK cells at typically high effector:target ratios. Approaches using custom-designed cell imaging systems have revealed that at low effector:target ratios, NK cells can kill target cells in a sequential or serial manner over a prolonged period [44] [45] [46] . It will be interesting to examine the effects of blocking ADAM17 on ADCC under conditions favoring serial killing, as the retention of cell surface CD16A on the activated NK cells would be predicted to affect the kinetics and efficiency of repeated engagement of antibody-bound tumor cells. The mouse cross-reactivity by MEDI3622 also provides an opportunity for in vivo pre-clinical studies. Unfortunately, mouse CD16 does not undergo ectodomain shedding [4] , and thus future studies will focus on a human hematopoietic cell and tumor xenograft mouse model.
Negative immunologic regulators help keep immune responses in check. Inhibitory receptors on NK cells play a constitutive role in suppressing activation signals [47] . ADAM17 fits the role of a negative checkpoint regulator of CD16A. CD16A shedding, however, occurs in a rapid manner and is perhaps a means of tuning the signaling of this potent activating receptor. Of interest is that tumor-associated NK cells have been shown to have decreased levels of CD16A in patients with ovarian cancer [14, 17] . Thus, prolonged ADAM17 induction may occur in the tumor microenvironment and contribute to suppressing NK cell effector functions. By blocking ADAM17 activity it may be possible to sustain NK cell production of anti-tumor cytokines in the presence of therapeutic antibodies for ovarian cancer as well as various other malignancies. It has been reported that ADAM17 can also directly degrade secreted IFNγ [48] , revealing another advantage for blocking ADAM17 as a cancer therapy. We cannot rule out that this may have contributed to the higher levels of IFNγ by NK cells when treated with MEDI3622. However, we do show that NK92 cells expressing ncCD16A released higher levels of IFNγ in the presence of antibody-bound tumor cells than NK92-CD16A cells, and that this was not further increased when NK92-ncCD16A were treated with MEDI3622.
In closing, therapeutic mAbs have become one of the fastest growing classes of drugs, and tumor-targeting mAbs are the most widely used and characterized immunotherapy for hematologic and solid tumors [49] . Several clinically successful antibodies utilize NK cell effector functions as a mechanism of action [2, 10] . MEDI3622 in combination with these therapeutic antibodies may provide a promising combination therapy to improve NK cell activity in the tumor microenvironment, in particular by enhancing their production of IFNγ to overcome tumor immunosuppression.
